INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Paper

Log P Value and Its Relevance in The Pharmaceutical Industry: A Comprehensive Review

V. Selvamani*, Dr. C. Sankar

Department of Pharmaceutics, KMCH College of Pharmacy, Coimbatore, INDIA.

ARTICLE INFO

Published: 19 Aug 2026
Keywords:
n-octanol/water partition coefficient, physicochemical descriptor, in-depth examination
DOI:
10.5281/zenodo.22014873

ABSTRACT

The logarithm of the n-octanol/water partition coefficient (log P) serves as a foundational physicochemical descriptor in medicinal chemistry and drug discovery. It quantifies molecular lipophilicity, a property that governs a drug candidate's journey through biological membranes, its target affinity, and its ultimate metabolic fate. This review provides an in-depth examination of log P, detailing its mathematical formulation, experimental determination methodologies, and algorithmic in silico prediction frameworks. Furthermore, we evaluate its critical role in predicting Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) profiles, its integration into structural filters like Lipinski's Rule of 5, and the emerging paradigms of Beyond Rule of 5 (bRo5) chemical spaces where dynamic lipophilicity landscapes dictate compound behavior

INTRODUCTION

The design and development of novel therapeutic entities is a multi-disciplinary endeavor that mandates a delicate equilibrium between pharmacodynamics (potency and selectivity) and pharmacokinetics (how the body processes the drug) [1,2]. Historically, a leading cause of drug candidate attrition during clinical development was poor bioavailability and unfavorable pharmacokinetics rather than a lack of efficacy [3]. To address this, structural property profiling has become deeply front-loaded in the early stages of discovery [4].

Among these properties, molecular lipophilicity—the relative affinity of a molecule for a lipidic vs. an aqueous environment—is widely considered a primary descriptor of drug-likeness [5,6]. Quantified standardly as $\log P$, this parameter profoundly affects passive membrane permeation, systemic distribution, plasma protein binding, hepatic clearance, metabolic vulnerability, and off-target toxicity [7-10]. This comprehensive

***Corresponding Author:** V. Selvamani
Address: *Lecturer, Department of Pharmaceutics, KMCH College of Pharmacy, Coimbatore, INDIA.*
Email ✉: selvamani.v@kmchcop.ac.in

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

review explores the thermodynamic principles of $\log P$, evaluates standard experimental and computational methods, and discusses its overarching relevance across the drug discovery pipeline.

2. Theoretical Background and Definitions

2.1 Thermodynamic Principles of Partitioning

The partition coefficient (P) reflects the equilibrium ratio of a neutral molecule's concentration between two immiscible phases [11,12]. By consensus, the pharmaceutical industry utilizes n-octanol and water (or an aqueous buffer) as the universal surrogate system. This specific biphasic system is favored because the long alkyl chain of n-octanol combined with its terminal hydroxyl group mimics the amphiphilic architecture of natural phospholipid bilayers [13]. Mathematically, for a non-ionizable compound, the partition coefficient is defined as:

$$P = \frac{[\text{Solute}]_{\text{octanol}}}{[\text{Solute}]_{\text{water}}}$$

The logarithmic value, $\log P$, scales this relationship linearly with the free energy of transfer ($\Delta G_{\text{transfer}}$) from the aqueous phase to the organic phase:

$$\log P = \frac{-\Delta G_{\text{transfer}}}{2.303RT}$$

where R is the universal gas constant and T is the absolute temperature.

2.2 Distinguishing $\log P$ and $\log D$

A crucial pitfall in medicinal chemistry is treating $\log P$ as a fixed value for ionizable molecules [14]. Because chemical compounds frequently contain weakly acidic or basic functional groups, they undergo ionization depending on the local pH of the physiological environment. The term $\log P$ is strictly reserved for the un-ionized (neutral) species [15].

To describe the effective lipophilicity of an ionizable substance at a specific pH, the distribution coefficient ($\log D$) must be used [16]. $\log D$ measures the ratio of the total concentration of all species (both ionized and un-ionized) in n-octanol versus the total concentration in the aqueous buffer:

$$\log D = \frac{[\text{Neutral}]_{\text{oct}} + [\text{Ionized}]_{\text{oct}}}{[\text{Neutral}]_{\text{aq}} + [\text{Ionized}]_{\text{aq}}}$$

For a simple monoprotic weak acid, the relationship between $\log P$ and $\log D$ is guided by the Henderson-Hasselbalch equation and expressed as [14]:

$$\log D_{\text{acid}} = \log P - \log(1 + 10^{\text{pH}-\text{p}K_a})$$

Conversely, for a monoprotic weak base [14]:

$$\log D_{\text{base}} = \log P - \log(1 + 10^{\text{p}K_a-\text{pH}})$$

3. Experimental Measurement Methodologies

Accurate experimental profiling of lipophilicity remains the gold standard, particularly for validating computational algorithms and resolving complex structural edge-cases [15,17].

3.1 Shake-Flask Method

The classical shake-flask approach represents the foundational standard for $\log P$ determination [11,12]. The compound is dissolved in mutually saturated phases of n-octanol and water, shaken rigorously until thermodynamic equilibrium is achieved, and separated. The concentration in each phase is subsequently quantified using ultraviolet-visible (UV-Vis) spectroscopy or liquid chromatography-mass spectrometry (LC-MS). Despite its high accuracy and reproducibility, it is notoriously labor-intensive, requires substantial sample quantities, suffers from low-throughput, and is prone to errors arising from emulsion formation [15,18].

3.2 High-Performance Liquid Chromatography (HPLC)

To circumvent the throughput limitations of the shake-flask method, reversed-phase HPLC (RP-HPLC) is extensively applied [19]. In this technique, the stationary phase acts as the lipid core, and an aqueous mobile phase acts as the hydrophilic medium. The capacity factor (k') is measured across various organic modifier fractions and extrapolated to 0% organic solvent ($\log k_w$) to correlate linearly with experimental $\log P$ values [19,20]. This approach requires minimal compound quantities, is tolerant to structural impurities, and can resolve multi-component mixtures within a single injection [4].

Method	Throughput	Material Required	Dynamic Range (log P)	Primary Advantages	Major Disadvantages
Shake-Flask [11,12,18]	Low	High (>1 mg)	-2 to +4	Thermodynamic gold standard; highly accurate.	Time-consuming; sensitive to impurities; emulsion formation.
RP-HPLC [4,19,20]	Medium-High	Low (<0.1 mg)	0 to +6	Rapid; impurity tolerant; screenable in mixtures.	Unreliable for highly charged species; columns require rigorous calibration.
Potentiometric Titration [14,15]	Medium	Medium (~0.5 mg)	0 to +5	Delivers $\log P$, $\log D$, and pK_a simultaneously.	Demands precise ionizable functional groups; poor for insoluble entities.

4. Computational *In Silico* Prediction Methods

Given the vast combinatorial space of chemical synthesis, computing $\log P$ values *in silico* prior to chemical synthesis is vital to filter out poorly optimized structures [21,22]. Current computational models generally fit into four primary structural strategies:

4.1 Substructure-Based and Fragmental Methods

These methodologies rely on the additive principle that a molecule's total lipophilicity is the summation of its component fragments [6,23].

- Atom-based (e.g., AlogP): Each atom is categorized based on its hybridizational and bonding environment, and predefined atomic hydrophobicity constants are aggregated [23,24].
- Fragment-based (e.g., ClogP): Developed originally by Hansch and Leo, these break the framework down into larger functional fragments, implementing electronic and steric correction factors to account for intramolecular interaction interferences [11,12,25].

4.2 Property-Based and Physics-Driven Approaches

Rather than relying on topological fragments, property-based systems evaluate whole-molecule

physical invariants like total solvent-accessible surface area (SASA), dipole moments, and electrostatic potentials. Advanced physics-driven methods—such as Molecular Dynamics (MD) simulations coupled with free energy perturbation (FEP) or conductor-like screening models for real solvents (COSMO-RS)—calculate the exact free energy of solvation to yield precise predictions, though they remain computationally expensive [7,26].

4.3 Machine Learning and Deep Learning Frameworks

Modern tools leverage deep learning architectures like Directed Message Passing Neural Networks (D-MPNN) and novel 3D structural descriptors (e.g., opt3DM) to map chemical topology directly to experimentally derived $\log P$ datasets like the SAMPL challenges [27,28].

5. The Critical Role of Log P in Drug Discovery and ADMET

The distribution of a drug candidate between hydrophilic and lipophilic environments guides its movement through biological barriers, as summarized below [5,29,30]:



5.1 Absorption and Bioavailability

Oral drug absorption occurs predominantly via passive transcellular diffusion through enterocytes. For this to happen efficiently, a molecule must balance hydrophilicity (to dissolve in the aqueous gastrointestinal lumen) with lipophilicity (to partition into and cross the hydrophobic core of cell membranes) [1,2]. Consequently, a parabolic relationship is commonly observed between $\log P$ and overall bioavailability; compounds within an optimal window ($\log P$ between 1 and 3) often exhibit optimal oral absorption [1,31].

5.2 Distribution and Central Nervous System (CNS) Penetration

To penetrate the blood-brain barrier (BBB) via passive diffusion, compounds generally require enhanced lipophilicity ($\log P \approx 2$ to 3.5) [32]. However, excessively high lipophilicity ($\log P > 5$) leads to heavy trapping within peripheral adipose tissues, high plasma protein binding (e.g., to human serum albumin), and rapid systemic clearance due to metabolic up-regulation [5,33].

5.3 Metabolism and Elimination

Lipophilic drugs are excellent substrates for phase I hepatic metabolic enzymes, specifically the Cytochrome P450 (CYP) superfamily [34]. Highly lipophilic structural frameworks fit comfortably into the hydrophobic catalytic pockets of CYPs, accelerating clearance [10]. Hydrophilic molecules ($\log P < 0$), conversely, bypass comprehensive hepatic transformation and are rapidly eliminated via renal excretion [30].

5.4 Toxicity and Safety Profiles

Elevated lipophilicity is tightly correlated with off-target toxicities, including hERG potassium channel inhibition (which causes cardiotoxic QT prolongation) and general cytotoxicity [9]. This phenomenon, termed "phospholipidosis," arises when highly lipophilic basic compounds partition irreversibly into lysosomes and intracellular lipid architectures [10,30].

6. Lipophilicity in Structural Filters and Molecular Design

6.1 Traditional Filters: Lipinski's Rule of 5

In 1997, Christopher Lipinski formulated the seminal "Rule of 5" (Ro5) to predict poor absorption or permeability based on structural traits [35]. The criteria dictate that poor oral absorption is more likely when:

- Molecular Weight (MW) > 500 Da
- Number of Hydrogen Bond Donors (HBD) > 5
- Number of Hydrogen Bond Acceptors (HBA) > 10
- Calculated $\log P$ (MlogP or ClogP) > 5 [6,35]

6.2 Modern Paradigms: Beyond Rule of 5 (bRo5)

Modern therapeutic modalities, such as Proteolysis Targeting Chimeras (PROTACs), macrocycles, and cyclic peptides, frequently operate in the "Beyond Rule of 5" (bRo5) structural space, featuring molecular weights well over 700 Da [36,37]. For these large, flexible chemical structures, static $\log P$ rules break down. Instead, these molecules rely on molecular chameleonism: adopting folded, intramolecularly hydrogen-bonded conformations in lipophilic environments (shielding polar groups to permeate membranes) and unfolding in aqueous environments to maintain solubility [38-40].

CONCLUSION

The partition coefficient ($\log P$) remains an indispensable parameter in modern drug design. While classical rules like Lipinski's Rule of 5 established $\log P \leq 5$ as a standard for oral drug-likeness, contemporary medicinal chemistry views lipophilicity not as a rigid boundary, but as a dynamic, context-dependent property. Through advanced *in silico* prediction modeling and innovative experimental setups like RP-HPLC, optimizing a compound's lipophilic profile continues to be a cornerstone strategy for reducing clinical attrition and successfully delivering safe, effective therapeutics.

REFERENCES

1. Veber DF, Johnson SR, Cheng HX, Smith BR, Ward KW, Kopple KD. Molecular

properties that influence the oral bioavailability of drug candidates. *J Med Chem.* 2002;45(12):2615-23.
2. Klimoszek D, Jeleń M, Morak-Młodawska B, Dołowy M. Evaluation of the lipophilicity of angularly condensed diquino- and quinonaphthothiazines as potential candidates for new drugs. *Molecules.* 2024;29(7):1683.
3. Leeson PD, Springthorpe B. The influence of drug-like properties on success in pharmaceutical R&D. *Nat Rev Drug Discov.* 2007;6(11):881-90.
4. Zheng B, West LM. Estimating the lipophilicity of natural products using a polymeric reversed phase HPLC method. *J Liquid Chromatogr Relat Technol.* 2009;33(1):118-32.
5. Waring MJ. Lipophilicity in drug discovery. *Expert Opin Drug Discov.* 2010;5(3):235-48.
6. Klimoszek D, Jeleń M, Dołowy M, Morak-Młodawska B. Study of the lipophilicity and ADMET parameters of new anticancer diquinothiazines with pharmacophore substituents. *Pharmaceuticals.* 2024;17(6):725.
7. Sun Y, Hou T, He X, Man VH, Wang J. Development and test of highly accurate endpoint free energy methods. 2: Prediction of logarithm of n-octanol–water partition coefficient ($\log P$) for druglike molecules using MM-PBSA method. *J Comput Chem.* 2023;44(14):1300-11.
8. Arnott JA, Planey SL. The influence of lipophilicity in drug discovery and development. *Expert Opin Drug Discov.* 2012;7(11):1027-42.
9. Hughes JD, Blagg J, Price DA, Leeson S, Central S, Houston JB, et al. Physiochemical drug properties associated with in vivo toxicity. *Bioorg Med Chem Lett.* 2008;18(17):4872-5.
10. Price DA, Blagg J, Jones L, Greene N, Wager T. Physicochemical drug properties associated with hepatic clearance and off-target toxicities. *Expert Opin Drug Metab Toxicol.* 2009;5(8):921-31.
11. Hansch C, Leo A. Substituent constants for correlation analysis in chemistry and biology. New York: Wiley; 1979.
12. Leo A, Hansch C, Elkins D. Partition coefficients and their uses. *Chem Rev.* 1971;71(6):525-616.
13. Abraham MH, Chadha HS, Whiting GS, Mitchell RC. Hydrogen bonding. Part 32. An analysis of water–octanol partition coefficients. *J Pharm Sci.* 1994;83(8):1085-1100.
14. Comer JEA, Tam KY. Lipophilicity profiles: Determination of $\log P$ and $\log D$ Lipo-profiles by potentiometric titration. In: Testa B, van de Waterbeemd H, editors. Lipophilicity in Drug Action and Toxicology. Weinheim: Wiley-VCH; 1996. p. 275-304.
15. Rutkowska E, Pajak K, Jozwiak K. Lipophilicity—methods of determination and its role in medicinal chemistry. *Acta Pol Pharm.* 2013;70(1):3-18.
16. Ermondi G, Vallaro M, Goetz G, Shalaeva M, Caron G. Experimental lipophilicity for beyond rule of 5 compounds. *Future Drug Discov.* 2019;1(1):FDD2.
17. Shalaeva M, Kenseth J, Lombardi F, Bastin MD. Measurement of $\log P$ using high-throughput methods. *J Pharm Sci.* 2008;97(11):4612-25.
18. Taylor S, Scullion P, Henderson J. Automated shake-flask methods for $\log P$ measurement in microfluidic architectures. *Drug Discov Today.* 2018;23(4):810-6.
19. Valko K, Du CM, Bevan C, Reynolds DP, Abraham MH. Rapid-gradient HPLC method for measuring drug lipophilicity and its

relevance in biopharmaceutics. *Curr Med Chem.* 2001;8(9):1137-46.
20. Henchoz Y, Guillarme D, Martel S, Rudaz S, Veuthey JL, Carrupt PA. Fast determination of lipophilicity by ultra-high-pressure liquid chromatography. *Anal Bioanal Chem.* 2009;394(7):1919-29.
21. Mannhold R, Poda GI, Ostermann C, Tetko IV. Calculation of molecular lipophilicity: State-of-the-art and comparison of $\log P$ methods on more than 96,000 compounds. *J Pharm Sci.* 2009;98(3):861-93.
22. Xing L, Glen RC. Novel methods for the prediction of $\log P$ values using artificial neural networks. *J Chem Inf Comput Sci.* 2002;42(4):796-805.
23. Wildman SA, Crippen GM. Prediction of physicochemical parameters by atomic contributions. *J Chem Inf Comput Sci.* 1999;39(5):868-73.
24. Ghose AK, Viswanadhan VN, Wendoloski JJ. A prediction of hydrophobic ($\log P$), steric, and electronic parameters of organic molecules for QSAR analysis. *J Comb Chem.* 1999;1(1):55-68.
25. Cheng A, Merz KM. Application of atomic constants to the estimation of $\log P$. *J Med Chem.* 2003;46(13):2711-20.
26. Klamt A, Eckert F, Diedenhofen M. Prediction of partition coefficients with COSMO-RS. *J Chem Inf Model.* 2009;49(4):729-35.
27. Bergazin TD, Tielker N, Zhang Y, Mao J, Gunner MR, Francisco K, et al. Evaluation of $\log P$, pK_a and $\log D$ predictions from the SAMPL7 blind challenge. *ChemRxiv.* 2021. doi:10.26434/chemrxiv.14461962.v1.
28. Zeng X, Ye X, Liu D, Cui N, Li X, Bao Y, et al. A new simple and efficient molecular descriptor for the fast and accurate prediction of $\log P$. *J Mater Inform.* 2025;5:61.
29. Waterbeemd H van de, Gifford E. ADMET *in silico* modelling: Towards prediction of human pharmacokinetics. *Nat Rev Drug Discov.* 2003;2(3):192-204.
30. Kerns EH, Di L. Drug-like properties: Concepts, structure design and methods: from ADME to toxicity optimization. Amsterdam: Elsevier; 2008.
31. Gleeson MP. Generation of a set of simple, interpretable ADME rules of thumb. *J Med Chem.* 2008;51(4):817-34.
32. Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. *NeuroRx.* 2005;2(4):541-53.
33. Wager TT, Hou X, Verhoest PR, Villalobos A. Moving beyond rules: The development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of drug-like properties. *ACS Chem Neurosci.* 2010;1(6):435-49.
34. Smith DA, Jones BC, Walker DK. Design of drugs involving competitive and non-competitive CYP450 interactions. *Med Res Rev.* 1996;16(3):243-66.
35. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliv Rev.* 1997;23(1-3):3-25.
36. Doak BC, Over B, Giordanetto F, Kihlberg J. Oral druggability space beyond the rule of 5: Insights from drugs and clinical candidates. *Chem Biol.* 2014;21(9):1115-42.
37. Matsson P, Kihlberg J. How much is too big? Reaching for the boundaries of the beyond rule of 5 space. *MedChemComm.* 2017;8(11):2013-24.
38. Rossi MS, Caron G, Ermondi G. Dynamic lipophilicity landscapes: Chameleonic properties of macrocycles and PROTACs in

modern discovery. *Drug Discov Today.* 2022;27(9):2415-23.

39. Whitty A, Zhong M, Viarengo L, Boyd EA, Towler CE. Quantifying the chameleonic behavior of macrocycles using apparent log *P* variations. *J Med Chem.* 2016;59(17):7733-42.
40. Gedeck P, Lewis R, Ward RA. Intramolecular hydrogen bonds: Tuning lipophilicity and permeability in bRo5 drug space. *Future Med Chem.* 2019;11(16):2011-25.

HOW TO CITE: V. Selvamani, Dr. C. Sankar, Log P Value and Its Relevance in The Pharmaceutical Industry: A Comprehensive Review, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 8, 2832-2839, https://doi.org/10.5281/zenodo.22014873